TY-JUR T1-R-R型肺纤维化（PF）：一种简单的视觉工具，用于评估健康相关的生活质量JF - 欧洲呼吸期刊JO - EUR RESPIR J DO - 10.1183 / 13993003.00917-2021 SP - 2100917Au - Scallan，Ciaran Au - Strand，Lauren Au - Hayes，Jennifer Au - Kadura，Suha Au - Collins，Bridget Au - Ho，Lawrence Au - Spada，Carolyn Au - CaneStaro，Will Au - Kolb，Martin Au - Raghu，GaneshY1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/05/28/13993003.00917-2021.Abstract n2 - 具有特发性肺纤维化（IPF）的理论患者经验有受损的健康相关质量生命（HRQOL）。已经开发了几种工具来客观地评估该患者人口中的HRQOL，但没有用于常规临床实践中的使用。目的是开发一种快速的特定工具，可用于常规诊所访问期间IPF的患者。方法是一种新颖简单开发了5项数值评定量表（NRS）并与另外两种先前验证的工具进行了比较。100岁的IPF患者在ILD中心管理，被招募完成R-Scale-PF，国王短暂的间质肺病问卷（K-Bild），以及Euroqol 5维5级调查问卷（EQ-5D-5L）除了肺功能和6分钟的步行试验中。和主要结果所有100名患者都成功完成了三个HRQOL工具，再次完成了53件，在后续访问时再次完成。内部一致性高（Cronbach的α0.825），楼层/天花板效果最小。与K-Bild（R = -0.713）和EQ-5D-5L（R = -0.665）相比，R-SCALE-PF的并发有效性与高于高度至高。并发有效性具有适度的生理措施（强制生命能力，R = -0.307，6分钟步行距离，R = -0.383）。 The R-Scale-PF demonstrated good known-groups validity when comparing scores across stages of disease severity.Conclusions The R-Scale-PF correlates well with the K-BILD and EQ-5D-5 L. It is hoped that this novel simple NRS tool subject to validation in patients from other centers will provide the opportunity to objectively measure HRQoL in routine clinical practice for patients with IPF.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Scallan has nothing to disclose.Conflict of interest: Dr. Strand has nothing to disclose.Conflict of interest: Dr. Hayes has nothing to disclose.Conflict of interest: Dr. Kadura has nothing to disclose.Conflict of interest: Dr. Collins reports personal fees from Boehringer Ingelheim, outside the submitted work; .Conflict of interest: Dr. Ho has nothing to disclose.Conflict of interest: Dr. Spada has nothing to disclose.Conflict of interest: Dr. Canestaro has nothing to disclose.Conflict of interest: Dr. Kolb reports grants from Canadian Pulmonary Fibrosis Foundation, other from Roche, other from Boehringer Ingelheim, grants from Canadian Institute for Health Research, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Roche, grants and personal fees from Liminal, other from European Respiratory Journal, personal fees from Third Pole, personal fees from MitoImmune, grants and personal fees from Pieris, personal fees from Abbvie, personal fees from DevPro Biopharma, personal fees from Horizon, personal fees from Algernon, personal fees from CSL Behring, outside the submitted work; .Conflict of interest: Dr. Raghu has nothing to disclose. ER -